Toronto Stock Exchange Symbol: CYT
MONTREAL, Aug. 30 /CNW/ - CryoCath Technologies Inc., the global leader
in cryotherapy products to treat cardiovascular disease, today announced the
addition of Jesse Penn to the Company's Board of Directors.
"We are pleased to welcome Jesse to the CryoCath Board of Directors,"
said Henri Vienneau, Chairman of the Board. "Jesse's extensive experience in
all facets of global high tech medical businesses make him a valuable addition
to our Board as we move towards the U.S. commercial launch of Arctic Front."
During his successful tenure with Johnson & Johnson, Mr. Penn served in
many different senior executive roles. These included Vice President, Global
Operations at various Johnson & Johnson businesses, including Cordis
Corporation, Vice President Global Marketing at Ethicon, and President Cordis
Cardiology. Previously, Mr. Penn served on the Board of Advisors for the
Howard University Business School and he currently sits on the Board of
Directors for DFB Pharmaceuticals, Inc. Mr. Penn received a Bachelor of
Science degree in Electrical Engineering from Howard University and graduated
from the Harvard University Program for Management Development.
CryoCath - www.cryocath.com - is a medical technology company that leads
the world in cryotherapy products to treat cardiovascular disease. With a
priority focus on providing physicians with a complete solution of catheter
products to treat cardiac arrhythmias, CryoCath has multiple products approved
in the U.S., across Europe and several ROW countries. The Company is
developing additional products to expand its pipeline of products to treat
This press release includes "forward-looking statements" that are subject
to risks and uncertainties, including with respect to the timing of regulatory
trials and their outcome. For information identifying legislative or
regulatory, economic, climatic, currency, technological, competitive and other
important factors that could cause actual results to differ materially from
those anticipated in the forward looking statements, see CryoCath's annual
report available at www.sedar.com under the heading Risks and Uncertainties in
the Management's Discussion and Analysis section.
For further information:
For further information: visit our website at www.cryocath.com, or
contact: Michael Moore, Investor Relations, Phone: (416) 815-0700 ext. 241,
Fax: (416) 815-0080, E-mail: firstname.lastname@example.org